Clinical TrialsThe Phase II trial on TFF TAC for preventing organ rejection in lung transplant patients shows promising results, as all six patients who completed the 12-week treatment opted to continue with the therapy.
Patient SafetyNo patients discontinued the TFF TAC therapy due to adverse events, and kidney function was maintained, highlighting the treatment's safety profile.
Transition SuccessAll eight patients successfully transitioned from oral tacrolimus to TFF TAC without any evidence of acute rejection, demonstrating the treatment's effectiveness.